FDA Matters recently published an important column on the need for FDA to maintain firm boundaries around all drug compounding, not just GLP-1’s. Otherwise, FDA risks creating two systems, one regulated, one not.
www.fdamatters.com/fdamatters/a...
#FDAMatters #DrugCompounding #GLP-1
0
0
0
0
